Immuno-oncology Combination Therapy
Oncology (Cancer)
Pre-clinicalActive R&D
Key Facts
About Chimeron Bio
Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.
View full company profileTherapeutic Areas
Other Oncology (Cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiPlex In Vivo CAR-T | Chimeron Bio | Pre-clinical |
| mRNA Cancer Vaccine | Chimeron Bio | Pre-clinical |